THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Cambridge biotech raises $40m to test Alzheimer's drug

Bay State firms increasingly rely on venture backing

Robin K. Meray tests compounds at Link, which is developing a drug for Alzheimer's and Parkinson's. Robin K. Meray tests compounds at Link, which is developing a drug for Alzheimer's and Parkinson's. (Suzanne Kreiter/Globe Staff)
By Todd Wallack
Globe Staff / September 30, 2008

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Despite turmoil in financial markets, venture capital hasn't completely dried up for the region's promising technology and biotechnology companies. (Full article: 443 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass